biostudies-literatureAmare ATBLRD VAIntramural NIH HHSNIDA NIH HHSNIMH NIH HHSDepartment of Health | National Health and Medical Research Council (NHMRC)5251-5261https://www.ebi.ac.uk/biostudies/studies/S-EPMC11041653biostudies-literatureUnknown28(12)Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental health disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not consistently effective, with only 30% of patients showing a favorable response to treatment. To provide personalized treatment options for bipolar patients, it is essential to identify prediction biomarkers such as polygenic scores. In this study, we developed a polygenic score for lithium treatment response (Li⁺_PGS) in patients with BD. To gain further insights into lithium's possible molecular mechanism of action, we performed a genome-wide gene-based analysis. Using polygenic score modeling, via methods incorporating Bayesian regression and continuous shrinkage priorsMolecular psychiatryAssociation of polygenic score and the involvement of cholinergic and glutamatergic pathways with lithium treatment response in patients with bipolar disorder.PMC11041653R01 MH059548R01 MH059556R01 MH059534R01 MH059567R01 MH059535R01 MH059533R01 MH060068R01 MH059553K02 DA021237Emerging Leadership Investigator Grant 2021 - 2008000ZIA MH002831Z01 MH002810I01 BX003431Trost SMcCarthy MJOzaki NCichon SBaune BTYildiz CGarnham JSZimmermann JFerensztajn-Rochowiak EAhmed MMitjans MNievergelt CMVieta EKahn JPBauer MWright AAkiyama KChen HCTekola-Ayele FJamain SZandi PPGryaznova ASquassina ASchmauß MKelsoe JLeboyer MHsu YHCervantes PKusumi IVeeh JChillotti CSimhandl CRitter PBacklund LPapiol SMitchell PBDietrich DNovak THauser JFischer AColom FO'Donovan CKonig BTurecki GHoffmann PStopkova PKonrad CLang FUHasler RRybakowski JKAlda MVogl TKittel-Schneider SWitt SHPisanu Cvon Hagen MDePaulo JRManchia MKuo PHBengesser SMcElroy SHashimoto RSlaney CMSpitzer CLanden MFullerton JMHerms SBellivier FFrisen LJager MLeckband SGAdorjan KGard SPerroud NGrof PCzerski PMSchulze TGSchofield PRSchweizer BWDannlowski UReif AGoes FSThalamuthu AReininghaus ELambert MShekhtman TEthofer TRietschel MMaj MMonteleone PNothen MMKohshour MOSenner FBudde MSchmidt JLaje GKoch MShilling PDSchalling MRouleau GAFigge CBiernacka JMGrigoroiu-Serbanescu MReimer JDel Zompo MClark SRSchulte ECWiltfang JPfennig ABermpohl FArolt VAdli MBirner ASeverino GArdau RStegmaier SSchubert KOHeilbronner UKraft VHeilbronner MMondimore FMAnghelescu IGBiere SGade KMarie-Claire CSchaupp SKReich-Erkelenz DForstner AJAndlauer TFMMatura SDalkner NFalkai PMillischer VFallgatter AJHartmann SDegenhardt FBenabarre AMartinsson LKassem LAkula NLavebratt CBhattacharjee AKAmare ATSchuster CFrye MACruceanu CTortorella AMcMahon FJKato THou LAubry JMFalkenberg IEtain BRohenkohl ACJuckel GJimenez EPetrova KPotash JBStamm TKalman JLHaussleiter ISRichard-Lepouriel HKircher TShimoda KArias BSchmitt AfalseAssociation of polygenic score and the involvement of cholinergic and glutamatergic pathways with lithium treatment response in patients with bipolar disorder.Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental health disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not consistently effective, with only 30% of patients showing a favorable response to treatment. To provide personalized treatment options for bipolar patients, it is essential to identify prediction biomarkers such as polygenic scores. In this study, we developed a polygenic score for lithium treatment response (Li⁺_PGS) in patients with BD. To gain further insights into lithium's possible molecular mechanism of action, we performed a genome-wide gene-based analysis. Using polygenic score modeling, via methods incorporating Bayesian regression and continuous shrinkage priors2023-01-01T00:00:00Z2023 Dec2026-07-15T08:19:01.711Z2026-07-01T03:12:28.494ZS-EPMC110416533743396710.1038/s41380-023-02149-1